Edmund P. Harrigan's most recent trade in Incyte Corp. was a trade of 367 Common Stock done at an average price of $68.1 . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 68.10 per share. | 30 Jun 2025 | 367 | 20,319 (0%) | 0% | 68.1 | 24,993 | Common Stock |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 9,216 | 9,216 | - | - | Non Qualfied Stock Option (right to buy) | |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 2,518 | 19,952 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 13,793 | 13,793 | - | - | Director Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Edmund P. Harrigan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2025 | 9,387 | 35,041 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Edmund P. Harrigan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2025 | 9,387 | 0 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 8,107 | 8,107 | - | - | Restricted Stock Units | |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 60.55 per share. | 31 Mar 2025 | 363 | 17,434 (0%) | 0% | 60.6 | 21,980 | Common Stock |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 69.07 per share. | 31 Dec 2024 | 339 | 17,071 (0%) | 0% | 69.1 | 23,415 | Common Stock |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 66.10 per share. | 30 Sep 2024 | 378 | 16,732 (0%) | 0% | 66.1 | 24,986 | Common Stock |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 60.62 per share. | 28 Jun 2024 | 409 | 16,354 (0%) | 0% | 60.6 | 24,794 | Common Stock |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 12,517 | 12,517 | - | - | Non Qualfied Stock Option (right to buy) | |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 2,830 | 15,945 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 15,959 | 15,959 | - | - | Director Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 9,387 | 9,387 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Edmund P. Harrigan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2024 | 6,652 | 25,654 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Edmund P. Harrigan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2024 | 6,652 | 0 | - | - | Restricted Stock Units | |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 56.97 per share. | 28 Mar 2024 | 413 | 13,115 (0%) | 0% | 57.0 | 23,529 | Common Stock |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 62.79 per share. | 29 Dec 2023 | 423 | 12,702 (0%) | 0% | 62.8 | 26,560 | Common Stock |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 62.25 per share. | 30 Jun 2023 | 390 | 11,890 (0%) | 0% | 62.3 | 24,278 | Common Stock |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 11,294 | 11,294 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 2,505 | 11,500 (0%) | 0% | 0 | Common Stock | |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 72.27 per share. | 31 Mar 2023 | 326 | 8,995 (0%) | 0% | 72.3 | 23,560 | Common Stock |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 80.32 per share. | 30 Dec 2022 | 302 | 8,669 (0%) | 0% | 80.3 | 24,257 | Common Stock |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 69.59 per share. | 19 Oct 2022 | 165 | 8,367 (0%) | 0% | 69.6 | 11,482 | Common Stock |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 66.64 per share. | 30 Sep 2022 | 250 | 8,202 (0%) | 0% | 66.6 | 16,660 | Common Stock |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 75.97 per share. | 30 Jun 2022 | 236 | 7,952 (0%) | 0% | 76.0 | 17,929 | Common Stock |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 9,124 | 9,124 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 2,144 | 7,716 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 14,368 | 14,368 | - | - | Director Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 8,552 | 8,552 | - | - | Restricted Stock Units | |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 79.42 per share. | 31 Mar 2022 | 240 | 5,572 (0%) | 0% | 79.4 | 19,061 | Common Stock |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 68.78 per share. | 30 Sep 2021 | 237 | 5,079 (0%) | 0% | 68.8 | 16,301 | Common Stock |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 84.13 per share. | 30 Jun 2021 | 208 | 4,842 (0%) | 0% | 84.1 | 17,499 | Common Stock |
| Acadia Pharmaceuticals Inc | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 11,637 | 11,637 | - | - | Director Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 11,045 | 11,045 | - | - | Director Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Edmund P. Harrigan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2021 | 8,552 | 19,002 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Edmund P. Harrigan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2021 | 8,552 | 0 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 6,652 | 6,652 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 6,391 | 6,391 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Edmund P. Harrigan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2021 | 6,391 | 10,450 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Edmund P. Harrigan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2021 | 6,391 | 0 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Edmund P. Harrigan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2021 | 3,059 | 4,059 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Edmund P. Harrigan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2021 | 3,059 | 0 | - | - | Restricted Stock Units | |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 8,010 | 8,010 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 1,923 | 4,634 (0%) | 0% | 0 | Common Stock | |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 81.27 per share. | 31 Mar 2021 | 219 | 2,711 (0%) | 0% | 81.3 | 17,798 | Common Stock |
| Incyte | Edmund P. Harrigan | Director | Grant, award, or other acquisition of securities at price $ 89.74 per share. | 30 Sep 2020 | 187 | 2,285 (0%) | 0% | 89.7 | 16,781 | Common Stock |
| Karuna Therapeutics Inc | Edmund P. Harrigan | Director | Sale of securities on an exchange or to another person at price $ 83.32 per share. | 12 Aug 2020 | 10,000 | 55,163 (0%) | 0% | 83.3 | 833,200 | Common Stock |